21.51
price up icon1.13%   0.24
after-market Handel nachbörslich: 22.00 0.49 +2.28%
loading
Schlusskurs vom Vortag:
$21.27
Offen:
$21.18
24-Stunden-Volumen:
631.28K
Relative Volume:
1.50
Marktkapitalisierung:
$1.56B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-153.64
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
+6.07%
1M Leistung:
+10.36%
6M Leistung:
-13.72%
1J Leistung:
+1.18%
1-Tages-Spanne:
Value
$21.05
$22.14
1-Wochen-Bereich:
Value
$20.43
$22.23
52-Wochen-Spanne:
Value
$16.56
$28.15

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name
Firmenname
Kiniksa Pharmaceuticals International Plc
Name
Telefon
(781) 431-9100
Name
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Name
Mitarbeiter
315
Name
Twitter
@kiniksa
Name
Nächster Verdiensttermin
2024-10-29
Name
Neueste SEC-Einreichungen
Name
KNSA's Discussions on Twitter

Vergleichen Sie KNSA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
KNSA
Kiniksa Pharmaceuticals International Plc
21.51 1.56B 384.10M -9.07M 11.10M -0.14
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
170.37 76.29B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.17 47.88B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.45 47.25B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.36 17.59B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.24 13.95B 612.78M -86.37M -62.91M -0.87

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-13 Eingeleitet Jefferies Buy
2024-05-03 Eingeleitet Wells Fargo Overweight
2020-06-29 Bestätigt BofA Securities Buy
2020-04-01 Eingeleitet BofA/Merrill Buy
2019-03-11 Eingeleitet Barclays Overweight
2018-12-12 Bestätigt Wedbush Outperform
2018-06-19 Eingeleitet JMP Securities Mkt Outperform
Alle ansehen

Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten

pulisher
Mar 07, 2025

Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex

Mar 07, 2025
pulisher
Mar 06, 2025

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey

Mar 06, 2025
pulisher
Mar 06, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World

Mar 05, 2025
pulisher
Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey

Mar 02, 2025
pulisher
Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Yahoo Finance

Mar 02, 2025
pulisher
Feb 28, 2025

12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 26, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan

Feb 24, 2025
pulisher
Feb 21, 2025

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire

Feb 21, 2025
pulisher
Feb 14, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain - Seeking Alpha

Feb 13, 2025
pulisher
Feb 13, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Consensus Target Price from Brokerages - Defense World

Feb 13, 2025
pulisher
Feb 13, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 By Investing.com - Investing.com Canada

Feb 13, 2025
pulisher
Feb 07, 2025

Kiniksa Pharmaceuticals International Plc (KNSA) Stock: Tracking the Weekly Performance - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Is Kiniksa Pharmaceuticals International Plc (KNSA) a opportunity to investors? - US Post News

Feb 06, 2025
pulisher
Feb 05, 2025

Keeping an Eye on Kiniksa Pharmaceuticals International Plc (KNSA) After Insider Trading Activity - Knox Daily

Feb 05, 2025
pulisher
Feb 04, 2025

Stock Market Recap: Kiniksa Pharmaceuticals International Plc (KNSA) Concludes at 18.88, a -3.67 Surge/Decline - The Dwinnex

Feb 04, 2025
pulisher
Jan 28, 2025

Exploring High Growth Tech Stocks in the United States - Simply Wall St

Jan 28, 2025
pulisher
Jan 20, 2025

Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World

Jan 20, 2025
pulisher
Jan 16, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com India

Jan 16, 2025
pulisher
Jan 14, 2025

Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.

Jan 14, 2025
pulisher
Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire

Jan 13, 2025
pulisher
Jan 13, 2025

Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan

Jan 13, 2025
pulisher
Jan 06, 2025

Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 06, 2025
pulisher
Dec 18, 2024

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com

Dec 18, 2024
pulisher
Dec 11, 2024

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Fmr LLC - Defense World

Dec 11, 2024
pulisher
Dec 11, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $593,997 By Investing.com - Investing.com Nigeria

Dec 11, 2024
pulisher
Dec 10, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $593,997 - Investing.com

Dec 10, 2024
pulisher
Dec 05, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $323,008 By Investing.com - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

Kiniksa Pharmaceuticals CFO sells shares worth $323,008 - Investing.com India

Dec 05, 2024

Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Kiniksa Pharmaceuticals International Plc-Aktie (KNSA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Tessari Eben
CHIEF OPERATING OFFICER
Feb 10 '25
Sale
19.57
14,000
273,980
81,975
$11.14
price up icon 2.86%
$34.35
price down icon 0.87%
$106.34
price up icon 6.10%
$113.04
price up icon 0.34%
$9.65
price up icon 1.47%
$131.24
price down icon 0.01%
Kapitalisierung:     |  Volumen (24h):